PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
The European Medicines Agency has given approval for the use of mastiha for mild dyspeptic disorders and skin inflammations [PMID:35276949].
In a randomized placebo-controlled pilot study of healthy volunteers with total cholesterol >200 mg/dl, a daily dose of 1g of crude CMG reduced total cholesterol by 11% after eight weeks [PMID:26311707].
A systematic review of RCTs and preclinical studies investigated the effects of Mastic Chios supplementation in IBD [PMID:37001176].
Mastic gum displays antibacterial properties, inhibits plaque accumulation, and provides effective antibacterial activity against periodontal bacteria [PMID:37147480].
Research indicates in vivo and in vitro activity against Helicobacter pylori, the main cause of gastric ulcers [PMID:22414110, PMID:35417884].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 35276949 (2022) — Overview of Chios Mastic Gum (Pistacia lentiscus) Effects on Human Health. · Nutrients
- 2.PMID: 37147480 (2023) — Mastic (Pistacia lentiscus) gum and oral health: a state-of-the-art review of the literature. · Journal of natural medicines
- 3.PMID: 32092498 (2020) — Traditional uses, phytochemistry and pharmacology of Chios mastic gum (Pistacia lentiscus var. Chia, Anacardiaceae): A review. · Journal of ethnopharmacology
- 4.PMID: 38892571 (2024) — Pistacia lentiscus: Phytochemistry and Antidiabetic Properties. · Nutrients
- 5.PMID: 39275256 (2024) — Chios Mastic Gum: A Promising Phytotherapeutic for Cardiometabolic Health.